Anti-PABPN1 antibody produced in rabbit

PABPN1 (poly(A) binding protein, nuclear 1) is a member of the PABP protein family, which resides in the nucleus. PABPC1 is a resident of the cytoplasm. PABPN1 was initially identified in vitro, as a protein facilitating the formation of RNA poly(A) tails. This protein has a ubiquitous expression pattern. This gene is localized to human chromosome 14q11.2-q13. The encoded protein is composed of 306 amino acids, and has a molecular weight of 32.8kDa. Its N-terminal is acidic in nature, and it contains a conserved RRM domain (RNA recognition motif) in its central region, followed by the C-terminal. There are 10 consecutive alanine residues in its N-terminal.

poly(A) binding protein, nuclear 1

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

PABPN1 (poly(A) binding protein, nuclear 1) is involved in pre-mRNA processing in the nucleus. It promotes the synthesis, as well as controls the length of the poly(A) tail at the 3′ end of the mRNA. It binds to the nascent mRNA transcript and controls the poly(A) tract elongation process in multicellular organisms. The protein may promote tumor aggressiveness by releasing the cancer cells from microRNA-mediated gene regulation. Mutations in this gene are associated with oculopharyngeal muscular dystrophy (OPMD) disorder. It is autosomal dominant in nature, and is a late onset muscular dystrophy disorder. It is characterized by drooping eyelids, difficulty in swallowing and weakness in proximal limbs.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST70406

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.